Silence Therapeutics (LON:SLN) Stock Price Passes Above 200 Day Moving Average – What’s Next?

Silence Therapeutics plc (LON:SLN) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 535 ($6.99) and traded as high as GBX 546 ($7.13). Silence Therapeutics shares last traded at GBX 535 ($6.99), with a volume of 913,528 shares trading hands.

Silence Therapeutics Trading Down 0.9 %

The business has a 50 day simple moving average of GBX 535 and a 200 day simple moving average of GBX 535. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.52 and a quick ratio of 4.36. The company has a market cap of £480.35 million and a price-to-earnings ratio of -11.01.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.